Johnson Financial Group, Inc. Neurocrine Biosciences Inc Transaction History
Johnson Financial Group, Inc.
- $2.06 Billion
- Q2 2024
A detailed history of Johnson Financial Group, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 10 shares of NBIX stock, worth $1,253. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10Holding current value
$1,253% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding NBIX
# of Institutions
621Shares Held
95.4MCall Options Held
661KPut Options Held
221K-
Black Rock Inc. New York, NY14.2MShares$1.78 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.26 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$577 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$309 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$296 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...